Toremifene

Established oncology SERM with comparable efficacy to tamoxifen in ER+ breast cancer. Off-label interest for gynecomastia prevention in androgen users.

A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.

Phase III trials demonstrate equivalent efficacy to tamoxifen in metastatic ER+ breast cancer. Lower risk of endometrial cancer than tamoxifen in some analyses. Also studied in prostate cancer (prevention of bone loss and fractures on ADT). Used off-label by anabolic steroid users for estrogen management.

• FDA-approved SERM for metastatic breast cancer
• May carry lower endometrial cancer risk than tamoxifen
• Preserves bone density on androgen deprivation therapy

Breast cancer: 60 mg once daily. Off-label SERM use: 30–60 mg/day (not evidence-based for this indication).

• Hot flashes
• Nausea
• QT prolongation
• Thromboembolic events
• Vaginal discharge

QT prolongation risk — avoid with other QT-prolonging drugs or in patients with hypokalemia/hypomagnesemia. Thromboembolic events. Endometrial changes. Hepatic dose considerations.

Oncology evidence is solid. Off-label use for gynecomastia prevention in steroid users lacks rigorous trial support.

• Muscle20
• Libido15